{"type":"trials","record":{"id":41737,"source_id":"clinicaltrials-gov","external_id":"NCT07129239","title":"High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","brief_summary":"The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg). EYLEA® HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections of EYLEA® HD followed by an extension of the treatment interval on the 4th visit. This was necessary since all patients in this study did not previously have treatment injections for wAMD. Currently there is not enough information on the best treatment regimen to use for patients that are switched to EYLEA® HD from EYLEA®. Health Canada currently recommends that EYLEA® HD is administered every month for the first 3 doses, followed by a treatment every 8 to 16 weeks. A total of 180 patients \\>18 years of age will participate in this study, which will be conducted at the Clinique de Retine de l'Est in Montreal, Quebec, Canada.","overall_status":"Not Yet Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Clinique de Retine de l'est","enrollment":180,"countries":["Canada"],"start_date":"2025-08-20","completion_date":"2027-02-01","last_update_date":"2025-08-19","source_url":"https://clinicaltrials.gov/study/NCT07129239","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"HEIRLOOM","age_range":"18 Years","comparator":"Loading interval group","organization":"Clinique de Retine de l'est","interventions":["Maintenance"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Central Retinal Thickness (CRT) — 6 and 12 month","Visual Acuity — 6 and 12 month","Number of injections — 6 and 12 month","Adverse events — 6 and 12 month","Presence of Subretinal Fluid (Yes/No) — 6 months and 12 months","Presence of Intraretinal Fluid (Yes/No) — 6 months and 12 months","Pigment Epithelial Detachment (PED) Type — 6 months and 12 months","Pigment Epithelial Detachment (PED) Height — 6 months and 12 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration (wAMD)","Maintenance"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07129239","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-08-20 to 2027-02-01","comparator":"Loading interval group","confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.863Z","intervention":["Maintenance"],"participants":180,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Central Retinal Thickness (CRT) — 6 and 12 month","Visual Acuity — 6 and 12 month","Number of injections — 6 and 12 month","Adverse events — 6 and 12 month","Presence of Subretinal Fluid (Yes/No) — 6 months and 12 months","Presence of Intraretinal Fluid (Yes/No) — 6 months and 12 months","Pigment Epithelial Detachment (PED) Type — 6 months and 12 months","Pigment Epithelial Detachment (PED) Height — 6 months and 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41737","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}